Diabetes patients in UK to get Eli Lilly drug, rivaling Ozempic
Both Novo Nordisk and Lilly have struggled to keep up with demand for the drugs, which are in shortage.
By Naomi Kresge and Madison Muller, Bloomberg
(Bloomberg) - Eli Lilly’s Mounjaro, a diabetes drug that’s also nearing approval for weight loss, is set to reach UK patients after winning the backing of England’s influential health-cost regulator, National Institute for Health and Care Excellence (NICE).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
